Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Friday, February 17, 2017
Ajinomoto North America, Inc., a wholly owned subsidiary of Ajinomoto Co., Inc., now offers to North American customers’ pharmaceutical-grade L-cystine that is produced using fermentation technology
read more
Wednesday, March 06, 2013
Ajinomoto Co., Inc. (“Ajinomoto Co.”; TYO: 2802) and Althea Technologies, Inc. (“Althea Technologies”), announced today that they have entered into a definitive agreement by which Ajinomoto Co. will acquire Althea Technologies, a leading provider of ...
read more
Ajinomoto OmniChem, provider of small molecule API, contract development and manufacturing services, has announced the completion of a commercial scale manufacturing campaign that involves adapting a traditional multi-step batch process into a ...
read more
Ajinomoto OmniChem, an innovative provider of small molecule API, contract development and manufacturing services, today announced the successful completion of a commercial scale manufacturing campaign that involved adapting a traditional multi-step ...
read more
Wednesday, March 31, 2021
Ajinomoto and Bright Peak Therapeutics announced a research collaboration and exclusive license agreement to incorporate AJICAP, Ajinomoto’s proprietary site-specific bioconjugation technology.
read more
Tuesday, December 18, 2018
Ajinomoto and XL-protein have established the efficient production of a PASylated proprietary GLP-1 variant with extended half-life at laboratory scale yielding >3 grams soluble protein per liter bacterial culture including facile purification from ...
read more
Wednesday, November 20, 2019
Akcea and Ionis announced the closing of the exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx.
read more
Monday, February 13, 2017
Akebia Therapeutics, a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), has entered into an exclusive agreement with Janssen Pharmaceutica, NV, one of the Janssen ...
read more
Akers Biosciences has acquired a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by Premas.
read more
Akers Biosciences announced Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype.
read more
Wednesday, August 08, 2012
Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today announced the appointment of Bruce Kutinsky as its Chief Operating Officer of its US operations effective September 1, 2012. Mr. Kutinsky was most recently the President of ...
read more
Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Federal Trade Commission (FTC) has voted to approve Akorn’s acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK). The unanimous vote in support of the transactions follows Akorn’s ...
read more
Akorn, Inc. and Hi-Tech Pharmacal Co., Inc. today announced that they have entered into a definitive agreement under which Akorn will acquire Hi-Tech for $640 million in cash.
read more
Akorn, Inc. today announced that it has entered into a definitive agreement to acquire VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440 million in cash.
read more
Akoya Biosciences Inc. and The Spatial Biology Company® announced a collaboration with AstraZeneca to advance new multiplex immunofluorescence (mIF) workflows and spatial biomarker signatures, based on Akoya’s Phenoptics™ platform. The agreement ...
read more